<DOC>
	<DOCNO>NCT00356018</DOCNO>
	<brief_summary>To determine , randomize , parallel open-label fashion , compliance rate once-daily extended-release divalproex sodium tablet ( Depakote-ER® , Abbott Labs ) versus multiple-daily dose valproic acid capsule ( Depakene® , Abbott Labs ) epilepsy population .</brief_summary>
	<brief_title>Compliance With Once-Daily Divalproex Extended-Release Tablets ( Depakote-ER ) Versus Multiple-Daily Dose Valproic Acid Capsules ( Depakene ) Epilepsy :</brief_title>
	<detailed_description>x_ Prospective x__ Single-center __ Multicenter x__ Open-label __ Double-blind __ Single-blind x_ Randomized ( please provide randomization ratio ) : 1:1 This population include patient whose seizure relatively well- controlled present conventional , enteric-coated , twice-daily three-times daily Divalproex sodium ( Depakote® , [ DR ] ) regimen . Patients DR monotherapy prefer , require . Partial onset seizure primarily generalize seizure represent study . Patients randomize 1:1 fashion . Group # 1 : 10 patient randomized IR-VPA , take 3 4 time day , total daily dose equivalent DR . The dose regimen likely take meal time receive IR-VPA tid ( q 8 h ) , additionally bedtime QID ( q 6 h ) regimen . The choice TID v QID regimen dictate patient ' total daily dose requirement , attempt keep number 250 mg capsule identical dose throughout day . Group # 2 : 10 patient randomized ER , take once-daily AM PM investigator 's discretion patient 's choice , since dose ER AM PM substantially differ plasma VPA concentration [ 17 ] . Once AM PM once-daily ER dose choose patient , change . ER once-daily dosing incorporate recommend dose-proportional increase 8-20 % total daily dose DR patient epilepsy ( 18 ) . However , one tablet strength ( 500 mg ER ) utilize , total daily dose round near 500 mg increment . A total 20 patient provide sufficient power ( 80 % ) adequately detect statistically ( p &lt; 0.05 ) clinically meaningful change compliance rate group , one exist . Compliance precision measure short-term study . Compliance , define number time multiple-daily IR-VPA dose ER dose actually take vs prescribed daily , tally computer-chip recording device ( MEMS unit [ 13 ] ) via patient 's daily diary / calendar . Precision , define actual time daily dose ER actually take ( multiple-daily dos IR-VPA actually take ) compare prescribe time ( + 15 min ) , document MEMS unit . It take 3 month recruit # 20 patient accord protocol . The total protocol last 49 70 day . There 21-day screening period per patient , follow 7-day period patient practice MEMS unit gain familiarity demonstrate competency device . After randomization Day 0 , 42 consecutive day prospective evaluation . From end study , time first abstract / manuscript submit : 2 month x__Abstract/manuscript/ poster assistance anticipate Washout period : N/A Screening Period : 0 21 day prior baseline observation . Baseline observation period : 7 day prior randomization . This period allow patient practice MEMS unit , gain familiarity demonstrate competency device . Treatment period : The treatment period forty-two ( # 42 ) day Randomization . A rapid , immediate conversion multiple-daily dosed DR once-daily divalproex-ER recommend adult epilepsy since simple maneuver understand low predict chance side effect ( 19 ) . Likewise , patient randomize IR-VPA group immediately convert DR multiple-daily dose IR-VPA without taper DR gradual titration upward IR-VPA . Taper period : N/A Age : adult ( 16 old ) Gender : male/female Disease study : Patients chronic , yet relatively stable partial /or generalize seizure disorder include study . Twenty patient currently currently undergo treatment enteric-coated divalproex [ DR ] treat physician elect change once-daily divalproex-ER candidate study . Ten patient assign group randomly , yield sufficient power make definite statement regard best conversion strategy use patient population . XX__ Depakote® Tablets ( Lead-in ) XX__ Depakote® ER - No Drug Required __ Depakote® Sprinkle - Depacon® XX_Depakene® Capsules Lead-in : Patients epilepsy already treat conventional , enteric-coated , delayed-release Depakote ( [ DR ] ) . Patients DR monotherapy prefer , patient may take additional AEDs . ACTIVE : Depakote-ER . For randomized group , 8-20 % mg dose increase utilized DR ER conversion , recommend Divalproex-ER package insert ( Abbott ) base upon publish evidence need compensate less bioavailability ER . Only 500 mg ER tablet use , total daily dose round near 500 mg . ACTIVE COMPARATOR : Depakene Capsules . Depakene liquid-filled capsule contain 250 mg IR-VPA . The total daily dose IR-VPA DR utilized . IR-VPA give TID ( q 8 h ) QID ( q 6 h ) , depend upon regimen allow identical number capsule give dose . Note : Compliance precision record either ER IR-VPA , AEDS , patient happen take concomitant AEDs . 1 ) Patients , age 16 , currently take Divalproex-DR seizure disorder ; 2 ) Other AEDs permit concurrently , although compliance record . Other medication co-morbid disease permit , provide plan change medication use treatment concomitant disorder expect . 3 ) Patients must demonstrate 75 % great compliance rate DR via calendar week familiarity MEMs unit . The threshold value 75 % choose since research show people take approximately 75 % AED ( ) prescribe ( 13,14 ) , numerical value frequently use determine whether retain patient clinical Phase 2a-3b industry-sponsored study . 1. patient recent history status epilepticus ; 2. patient refractory unstable epilepsy ; 3. patient acute illness require change concurrent drug ; 4. patient unwilling change present DR regimen divalproex-ER IR-VPA . 5 . Patients unwilling unable utilize MEMs monitoring unit ; 6 . Pregnant lactating woman . IRB approval seek . After appropriate IRB approval , write , informed consent obtain patient participate . Patients either Group instruct take ER IR-VPA accord PI 's usual practice , without different special coach prompt technique enhance compliance throughout study . Patients observe closely physicians allied health personnel weekly basis , actual visit study center ( Days 0 , +14 , +28 &amp; +42 via phone Days +7 , +21 &amp; +35 . Blood work , include CBC , platelet count , LFTs , serum chemistry panel total valproate measure prior end study Day +42 post-randomization . Criteria premature discontinuation safety reason : 1 . Patients pass screen demonstrate proficiency competence MEMs monitor unit 7-day period prior randomization ; 2 . Patients 50 % increase seizure frequency compare historic baseline , development seizure require hospitalization time study ; 3 . Patients clinically significant increase number severity AEs , determine investigator ; 4 . Patients MEMs ( data immediately accessible available ) calendar-documented compliance rate &lt; 35 % time study . 5 . Patients MEMs ( data immediately accessible available ) calendar-documented compliance rate &gt; 35 % &lt; 75 % three separate occasion two consecutive occasion study . Primary Measures : The primary efficacy parameter difference mean compliance rate ( define # take divided # dos prescribe ) ER vs IR-VPA group Day + 42 . Secondary Measures : 1 ) The change compliance rate Day 0 Day +42 compare group ; 2 ) The precision dose administration , determine number dos administer within + 15 min assign time compare dose time course study two group ; 3 ) Drop rate group , due lack seizure control , adverse effect noncompliance , compare group . x_Statistical analysis assistance may require None foreseen . Patients select study , upon recommendation order physician , switch multiple-daily dose divalproex-DR divalproex extended-release formulation , administer once-daily IR-VPA . This project consider `` research '' virtue randomization epilepsy patient two different group , utilizing dosage formulation regimens commonly encountered clinical practice .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>1 ) Patients , age 16 , currently take DivalproexDR seizure disorder ; 2 ) Other AEDs permit concurrently , although compliance record . Other medication comorbid disease permit , provide plan change medication use treatment concomitant disorder expect . 3 ) Patients must demonstrate 75 % great compliance rate DR via calendar week familiarity MEMs unit . The threshold value 75 % choose since research show people take approximately 75 % AED ( ) prescribe ( 13,14 ) , numerical value frequently use determine whether retain patient clinical Phase 2a3b industrysponsored study . 1 ) patient recent history status epilepticus ; 2 ) patient refractory unstable epilepsy ; 3 ) patient acute illness require change concurrent drug ; 4 ) patient unwilling change present DR regimen divalproexER IRVPA . 5 ) Patients unwilling unable utilize MEMs monitoring unit ; 6 ) Pregnant lactate woman .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Compliance</keyword>
</DOC>